Santhera Publishes Timeline of the Reverse Share Split
29 Juin 2023 - 7:00AM
Santhera Publishes Timeline of the Reverse Share Split
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN
THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE
UNLAWFUL TO DO SO.
Ad hoc announcement pursuant to Art. 53 LR
Pratteln, Switzerland,
June 29,
2023 – Santhera Pharmaceuticals
(SIX: SANN) announces
the timeline of the reverse share split in
the ratio 10:1 which was approved by
shareholders at the Annual
General Meeting held on
June 27,
2023, with a large majority.
-
June 30,
2023: Last trading day of old shares
(ISIN: CH0027148649) on SIX Swiss Exchange
-
July 3,
2023: First trading day of new shares
(ISIN: CH1276028821) on SIX Swiss Exchange (ex-date)
The reverse share split may result in fractions
of new registered shares of the Company for individual
shareholders. This is the case if shareholders hold a number of
Santhera shares that is not divisible by 10 as of June 30,
2023. Remaining shareholdings between 1 and 9 are rounded down and
affected shareholders will receive a cash compensation (in CHF) for
their fractions corresponding to a three-day volume-weighted
average price (VWAP) of the Santhera share on the SIX Swiss
Exchange prior to the ex-date of the reverse share split.
The new shares issued following the reverse
stock split will have a new International Securities Identification
Number (ISIN) while the existing shares held prior to the reverse
stock split will be canceled. For technical reasons, shareholders
who wish to continue exercising their voting rights are asked to
ensure a re-registration in the Company’s share register.
Further information regarding the reverse share
split can be found in the AGM invitation and the Q&A on
Santhera's website here.
About SantheraSanthera
Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical
company focused on the development and commercialization of
innovative medicines for rare neuromuscular and pulmonary diseases
with high unmet medical need. The Company has an exclusive license
for all indications worldwide to vamorolone, a dissociative steroid
with novel mode of action, which was investigated in a pivotal
study in patients with Duchenne muscular dystrophy (DMD) as an
alternative to standard corticosteroids. For vamorolone in the
treatment of DMD, Santhera has a new drug application (NDA) under
review by the U.S. FDA, a marketing authorization application (MAA)
under review by the European Medicines Agency (EMA) and an MAA
submitted to the UK Medicines and Healthcare products Regulatory
Agency (MHRA). The clinical stage pipeline also includes
lonodelestat to treat cystic fibrosis (CF) and other neutrophilic
pulmonary diseases. Santhera out-licensed rights to its first
approved product, Raxone® (idebenone), outside North America and
France for the treatment of Leber's hereditary optic neuropathy
(LHON) to Chiesi Group. For further information, please visit
www.santhera.com.
Raxone® is a trademark of Santhera
Pharmaceuticals.
For further information please
contact: public-relations@santhera.com orEva Kalias, Head
Investor Relations & CommunicationsPhone: +41 79 875 27
80eva.kalias@santhera.com
Disclaimer / Forward-looking
statements This document does not constitute an offer to
subscribe for, buy or sell any of the securities mentioned herein
or any other securities in any jurisdiction. The securities
mentioned herein have not been and will not be registered under the
U.S. Securities Act of 1933, as amended (the Securities
Act), and may not be offered or sold in the United States
absent registration or exemption from registration under the
Securities Act.
This communication does not constitute an offer
or invitation to subscribe for or purchase any securities of
Santhera Pharmaceuticals Holding AG. This publication may contain
certain forward-looking statements concerning the Company and its
business. Such statements involve certain risks, uncertainties and
other factors which could cause the actual results, financial
condition, performance or achievements of the Company to be
materially different from those expressed or implied by such
statements. Readers should therefore not place undue reliance on
these statements, particularly not in connection with any contract
or investment decision. The Company disclaims any obligation to
update these forward-looking statements.
# # #
- 2023 06 29_RSS-Timeline_e_final
Santhera Pharmaceuticals (LSE:0QN1)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Santhera Pharmaceuticals (LSE:0QN1)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
